Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Carcinoma, Non-Small-Cell LungColorectal NeoplasmsEndometrial NeoplasmsOvarian NeoplasmsPancreatic NeoplasmsBiliary Tract Neoplasms
Interventions
DRUG

LY3537982

Oral

DRUG

Pembrolizumab

Intravenous

DRUG

Cetuximab

Intravenous

DRUG

Pemetrexed

Intravenous

DRUG

Cisplatin

Intravenous

DRUG

Carboplatin

Intravenous

Trial Locations (49)

920

RECRUITING

Kanazawa University Hospital, Kanazawa

2010

RECRUITING

St Vincent's Hospital Sydney, Sydney

2065

RECRUITING

Royal North Shore Hospital, St Leonards

3199

RECRUITING

Peninsula and Southeast Oncology, Frankston

5000

RECRUITING

Cancer Research SA, Adelaide

6009

RECRUITING

Linear Clinical Research, Nedlands

10016

RECRUITING

NYU Langone, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10408

RECRUITING

National Cancer Center, Goyang-si

11501

RECRUITING

NYU Langone Health- Long Island, Mineola

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

16247

RECRUITING

The Catholic University of Korea, St. Vincent's Hospital, Suwon

22031

RECRUITING

Inova Health System IRB, Fairfax

RECRUITING

USO-Virginia Cancer Specialists, PC, Fairfax

27103

RECRUITING

Novant Health Cancer Institute - Forsyth, Winston-Salem

27599

RECRUITING

The University of North Carolina at Chapel Hill, Chapel Hill

28204

RECRUITING

Novant Health Cancer Institute - Elizabeth, Charlotte

31052

RECRUITING

Institut Claudius Regaud - IUCT Oncopole, Toulouse

32803

RECRUITING

AdventHealth Orlando, Orlando

33076

RECRUITING

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux

34236

RECRUITING

Florida Cancer Specialists, Sarasota

34298

RECRUITING

Institut du Cancer de Montpellier - Val d'aurelle, Montpellier

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

37203

RECRUITING

Sarah Cannon Cancer Center, Nashville

46202

RECRUITING

Indiana Univ Melvin & Bren Simon Cancer Center, Indianapolis

46250

RECRUITING

Community Health Network, Indianapolis

58128

RECRUITING

Chonnam National University Hwasun Hospital, Hwasun-gun

69008

RECRUITING

Centre Leon Berard, Lyon

70809

RECRUITING

Mary Bird Perkins Cancer Center, Baton Rouge

84119

RECRUITING

START Mountain Region, West Valley City

90033

RECRUITING

USC Norris Cancer Hospital, Los Angeles

92868

RECRUITING

Chao Family Comprehensive Cancer Ctr., Orange

94805

RECRUITING

Gustave Roussy, Villejuif

06510

RECRUITING

Yale-New Haven Hospital, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston

03756

RECRUITING

Dartmouth-Hitchcock Medical Center, Lebanon

19111-2497

RECRUITING

Fox Chase Cancer Center, Philadelphia

37212-6303

RECRUITING

Vanderbilt Univeristy School of Medicine, Nashville

78229-3307

RECRUITING

South Texas Accelerated Research Therapeutics (START), San Antonio

53792-4108

RECRUITING

University of Wisconsin-Madison Hospital and Health Clinic, Madison

T6G 1Z2

RECRUITING

Cross Cancer Institute, Edmonton

M4X 1K9

RECRUITING

Princess Margaret Hospital (Ontario), Toronto

464-8681

RECRUITING

Aichi Cancer Center Hospital, Nagoya

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

060-8648

RECRUITING

Hokkaido University Hospital, Sapporo

104-0045

RECRUITING

National Cancer Center Hospital, Chuo-ku

641-8510

RECRUITING

Wakayama Medical University Hospital, Wakayama

03080

RECRUITING

Seoul National University Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY